Clinical trial ZIRCON
A confirmatory, prospective, open-label, multi-centre phase 3 study to evaluate diagnostic performance of 89Zirconium-labelled girentuximab(89Zr-TLX250) to non-invasively detect clear cell renal cell carcinoma (ccRCC) by positron emission tomography/CT (PET/CT) imaging in patients with indeterminate renal masses (ZIRCON Study)
| Cancers | |
|---|---|
| Organ | Kidney |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Telix International Pty Ltd |
| EudraCT Identifier | 2018-002773-21 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03849118 |
| Inclusion criteria | *Single indeterminate renal mass |
| Last update |